Description
Trastuzumab emtansine also known as ado-trastuzumab emtansine and sold under the trade name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1.
In the United States, ado-trastuzumab emtansine was approved specifically for treatment of HER2-positive metastatic breast cancer (mBC) in patients who have been treated previously with trastuzumab and a taxane (paclitaxel or docetaxel), and who have already been treated for mBC or developed tumor recurrence within six months of adjuvant therapy.
Approval was based on the EMILIA study, a phase III clinical trial that compared trastuzumab emtansine versus capecitabine (Xeloda) plus lapatinib (Tykerb) in 991 people with unresectable, locally advanced or metastatic HER2-positive breast cancer who had previously been treated with trastuzumab and taxane chemotherapy. This trial showed improved progression-free survival in patients treated with trastuzumab emtansine (median 9.6 vs. 6.4 months), along with improved overall survival (median 30.9 vs. 25.1 months) and safety.
HOW AND WHERE TO BUY ado-trastuzumab emtansine for injection?
You can order ado-trastuzumab emtansine for injection through Medvitaz Pharma Solutions under Named Patient Program (NPP). Medvitaz provides patients and physicians access to commercialy approved medicines that are not available to them in their own country. Medvitaz objectives is to make quality medicines available at affordable prices for patients and physicians. To get best retail price/cost of ado-trastuzumab emtansine for injection in India, Call 8750295029 or Email [email protected]. FDA approved drugs of Australia, Canada, Delhi, EU, India, New Zealand, Singapore, Switzerland, Turkey & USA.